Another agent undergoing active clinical investigation is BL-8040, a high affinity peptide CXCR4 inhibitor with a prolonged pharmacodynamic efficacy and direct pro-apoptotic activity on AML blasts (24, 25). This evidence concerns the gene CXCR4 and acute myeloid leukemia.